首页> 外文期刊>BMC Health Services Research >Establishing a hospital transfusion management system promotes appropriate clinical use of human albumin in Japan: a nationwide retrospective study
【24h】

Establishing a hospital transfusion management system promotes appropriate clinical use of human albumin in Japan: a nationwide retrospective study

机译:建立医院输血管理系统促进日本人白蛋白的适当临床应用:全国回顾性研究

获取原文
       

摘要

BACKGROUND:Despite international recommendations to establish hospital transfusion management systems to promote appropriate use of blood products, the general efficacy of establishing such systems has not been proven. This study aimed to validate the effect of establishing such systems for promoting the appropriate use of human albumin.METHODS:In this retrospective observational study, we used a Japanese Diagnosis Procedure Combination (DPC) database from fiscal year 2012 to 2016, which included inpatient records from approximately 1200 hospitals for payment processes in the national medical insurance system. From this existing database, containing approximately 8 million inpatient records per year, we selected patients with emergency due to "bleeding," "sepsis," and "burn injury," by using the International Classification of Diseases and Injuries 10th revision (ICD-10) codes, and hospitals that had one or more patients for each disease group in each fiscal year. We conducted multivariable logistic regression analysis to estimate the relationship between human albumin administration and the state of the hospital transfusion management system. We evaluated temporal trends of mortality rate and length of stay as an indicator of care quality.RESULTS:Overall, 139,853 eligible patients admitted to 682 hospitals were selected. The results of the multivariable logistic regression analysis show that patients who were admitted to hospitals with an established hospital transfusion department introducing good practice criteria of blood products were less likely to be administered human albumin compared with those who were admitted to hospitals not introducing it, by approximately 30% for each of the three disease groups; adjusted odds ratios (95% confidential intervals) were 0.70 (0.59-0.83), 0.75 (0.69-0.81), and 0.71 (0.58-0.87) in the "bleeding," "sepsis," and "burn injury" groups, respectively. The temporal trends evaluation shows that there were no increasing trends of mortality rate and average length of stay against decreasing trends of human albumin administration in any disease groups.CONCLUSIONS:Establishing a hospital transfusion department responsible for promoting appropriate clinical use of blood products could reduce human albumin administration for critically ill patients without loss of care quality. These findings provide support for policy makers and hospital managers to consider establishing such systems.
机译:背景:尽管国际建议建立了医院输血管理系统,以促进适当使用血液产品,但建立此类系统的一般疗效尚未得到证实。本研究旨在验证建立促进适当使用人白蛋白的系统的效果:在这个回顾性观察研究中,我们使用了2012年财政年度至2016年的日本诊断程序组合(DPC)数据库,其中包括住院记录从大约1200家医院到国家医疗保险制度的付款流程。从这个现有数据库中,每年包含大约800万存住所记录,我们通过使用国际疾病和伤害的国际分类(ICD-10 )在每个财政年度为每个疾病组有一个或多个患者的代码和医院。我们进行了多变量的逻辑回归分析,以估算人类白蛋白给药与医院输血管理系统之间的关系。我们评估了月度死亡率的时间趋势和作为护理质量指标的逗留时间。结果:总体而言,139,853名符合条件的患者入住682家医院。多变量逻辑回归分析结果表明,与已建立的医院输血部门承认医院的患者引入良好的血液产品标准,与那些被录取的未介绍它的医院录取的人相比,人类白蛋白不太可能施用。三种疾病群体中的每一个约30%;调整后的优势比(95%的机密间隔)分别为0.70(0.59-0.83),0.75(0.69-0.81)和0.71(0.58-0.87)分别在“出血”,“脓毒症”和“烧伤伤害”组中。时间趋势评估表明,在任何疾病群体中,死亡率率没有增加的死亡率和平均保持趋势,以减少人类白蛋白给药群体的趋势。结论:建立负责促进血液产品的适当临床用途的医院输血部门可以减少人类患有危重病患者的白蛋白给药而不损失护理品质。这些调查结果为政策制定者和医院管理人员提供了支持,以考虑建立此类系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号